Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 1/20 | 0.42 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.42 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.42 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.42 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.42 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.42 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.42 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 7/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349865 | 0.83 | MEN1 (0.46) | BRD4KDM4EMEN1HPGDKMT2A | |
| SCHEMBL1349694 | 0.80 | BRD4 (0.40) | IDO1TDO2BRD4KDM4EMEN1 | |
| SCHEMBL1348736 | 0.77 | BRD4 (0.40) | BRD4KDM4EMEN1HPGDKMT2A | |
| SCHEMBL1347230 | 0.74 | KMT2A (0.41) | TACR1MEN1KMT2A | |
| SCHEMBL20569604 | 0.70 | KDM4E (0.53) | BRD4KDM4EMEN1HPGDKMT2A | |
| SCHEMBL1349386 | 0.68 | MAPT (0.49) | KDM4EKCNN4MEN1KMT2A | |
| Efetozole SCHEMBL21698044 | 0.65 | BRD4 (0.51) | BRD4KDM4EMEN1HPGDKMT2A | |
| Efetozole SCHEMBL2109012 | 0.65 | BRD4 (0.51) | BRD4KDM4EMEN1HPGDKMT2A | |
| SCHEMBL12402673 | 0.64 | TACR1 (0.54) | TACR1IDO1TDO2 | |
| SCHEMBL12154096 | 0.64 | CASR (0.53) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063090-B2 | Mineralocorticoid receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-11-22 | — | — | US | claimed |
| US-20100069452-A1 | MINERALOCORTICOID RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-03-18 | — | — | US | claimed |
| EP-2139489-A2 | MINERALOCORTICOID RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008118319-A2 | MINERALOCORTICOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-02 | — | — | WO | claimed |
| US-8063090-B2 | Mineralocorticoid receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063090-B2 | Mineralocorticoid receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063090-B2 | Mineralocorticoid receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100069452-A1 | MINERALOCORTICOID RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-03-18 | — | — | US | disclosed |
| US-20100069452-A1 | MINERALOCORTICOID RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-03-18 | — | — | US | disclosed |
| US-20100069452-A1 | MINERALOCORTICOID RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-03-18 | — | — | US | disclosed |
| WO-2008118319-A2 | MINERALOCORTICOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069452-A1 | MINERALOCORTICOID RECEPTOR MODULATORS | NR3C2, MC2R, NR3C1 | ATP1A1 2718/4885ATP1B1 3524/4885ATP1A3 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.